The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; Murdoch Children's Research Institute, Melbourne, VIC, Australia.
Clinical Research Department, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Hospital for Tropical Diseases, London, UK.
Lancet Glob Health. 2018 Oct;6(10):e1132-e1138. doi: 10.1016/S2214-109X(18)30397-8.
Mass drug administration has made a major contribution to the public health control of several important neglected tropical diseases. For settings with more than one endemic disease, combined mass drug administration has potential practical advantages compared with separate programmes but needs confirmation of feasibility and safety. We undertook a study of mass drug administration in the Solomon Islands for trachoma and scabies control using ivermectin and azithromycin, key drugs in the control of neglected tropical diseases worldwide.
The entire population of Choiseul province, Solomon Islands, was eligible to participate. An azithromycin-based mass drug administration regimen was offered in line with standard recommendations for trachoma elimination (oral azithromycin or topical tetracycline). An ivermectin-based mass drug administration regimen was offered at the same time (oral ivermectin or topical permethrin), with a further dose 7-14 days later, using a modified version of a regimen demonstrated to be effective for scabies control. All participants underwent safety assessments 7-14 days later. Participants in ten randomly selected sentinel villages underwent a more detailed safety assessment. Routine health system reports of hospital or clinic admissions and deaths were also obtained to compare health outcomes in the 12 month period before and after the mass drug administration.
The study enrolled 26 188 participants, 99·3% of the estimated resident population as determined at the 2009 census. Of those enrolled, 25 717 (98·2%) received the trachoma regimen and 25 819 (98·6%) received the first dose of the scabies regimen between Sept 1, and Oct 2, 2015. A second dose of the scabies regimen was received by 21 931 (83·7%) of participants. Adverse events, all mild and transient, were recorded in 571 (2·6%) of the entire study population and 58 (4·1%) of participants in the ten sentinel villages. In the 12 months before and after the mass drug administration the numbers of hospital admissions (1530 vs 1602) and deaths (73 vs 83) were similar. In the month after the mass drug administration, 84 individuals were admitted to hospital and two died, compared with a monthly median of 116 admissions (IQR 106-159) and six deaths (IQR 4-7) in the 12 months before and after the mass drug administration.
In the largest trial so far involving coadministration of regimens based on ivermectin and azithromycin, the combination was safe and feasible in a population of more than 26 000 people. Coadministration of mass drug administration based on these two drugs opens up new potential for the control of neglected tropical diseases.
International Trachoma Initiative, Murdoch Children's Research Institute, Scobie and Claire Mackinnon Trust, Wellcome Trust.
大规模药物治疗在控制几种重要的被忽视热带病方面作出了重大贡献。对于存在多种地方病的地区,与单独方案相比,联合大规模药物治疗具有潜在的实际优势,但需要确认其可行性和安全性。我们对所罗门群岛的沙眼和疥疮进行了大规模药物治疗,使用了伊维菌素和阿奇霉素,这是全球控制被忽视热带病的关键药物。
所罗门群岛的全部人口均有资格参加Choiseul 省的研究。根据消除沙眼的标准建议(口服阿奇霉素或局部四环素),提供了阿奇霉素为基础的大规模药物治疗方案。同时提供了伊维菌素为基础的大规模药物治疗方案(口服伊维菌素或局部扑灭司林),7-14 天后再给予一剂,使用了一种经证明对疥疮控制有效的方案的改良版本。所有参与者在 7-14 天后接受安全性评估。在 10 个随机选择的哨点村庄中,有部分参与者接受了更详细的安全性评估。还获得了常规卫生系统报告的医院或诊所入院和死亡情况,以比较大规模药物治疗前后 12 个月的健康结果。
研究共纳入 26188 名参与者,占 2009 年人口普查确定的估计居民人口的 99.3%。在登记的参与者中,25717 人(98.2%)接受了沙眼治疗方案,25819 人(98.6%)在 2015 年 9 月 1 日至 10 月 2 日之间接受了疥疮治疗方案的第一剂。21931 人(83.7%)接受了疥疮治疗方案的第二剂。在整个研究人群中,有 571 人(2.6%)和 10 个哨点村庄的 58 人(4.1%)记录了不良事件,均为轻度和短暂的。在大规模药物治疗前后的 12 个月中,医院入院人数(1530 人与 1602 人)和死亡人数(73 人与 83 人)相似。在大规模药物治疗后一个月,有 84 人住院,2 人死亡,而在大规模药物治疗前后的 12 个月中,每月的中位数为 116 人入院(IQR 106-159)和 6 人死亡(IQR 4-7)。
在迄今为止涉及伊维菌素和阿奇霉素联合治疗方案的最大试验中,该联合方案在超过 26000 人的人群中是安全且可行的。基于这两种药物的大规模药物联合治疗为控制被忽视的热带病开辟了新的潜力。
国际沙眼倡议、默多克儿童研究所、斯科比和克莱尔·麦金农信托、惠康信托。